Results 251 to 260 of about 541,152 (293)
Some of the next articles are maybe not open access.
Oncology Times, 2012
The role of radiotherapy (RT) for metastatic breast cancer is broken down into three settings: the first and most common is palliative radiotherapy, the second is stereotactic RT for oligometastases instead of surgery, and the third is the irradiation of the breast for locoregional control.
Alanyalı S.D., Ozsaran Z.
openaire +3 more sources
The role of radiotherapy (RT) for metastatic breast cancer is broken down into three settings: the first and most common is palliative radiotherapy, the second is stereotactic RT for oligometastases instead of surgery, and the third is the irradiation of the breast for locoregional control.
Alanyalı S.D., Ozsaran Z.
openaire +3 more sources
Clinical Orthopaedics and Related Research, 2003
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +4 more sources
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +4 more sources
Oncology Times, 2006
This fourteenth article in our series on breast disease gives an overview of what to look for in the patient with a past history of early breast cancer and how to assess and support the patient with metastatic breast cancer in the general practice setting.
Amanda, Stevanovic +2 more
+5 more sources
This fourteenth article in our series on breast disease gives an overview of what to look for in the patient with a past history of early breast cancer and how to assess and support the patient with metastatic breast cancer in the general practice setting.
Amanda, Stevanovic +2 more
+5 more sources
Current Opinion in ONCOLOGY, 1993
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Current Opinion in Oncology, 1996
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
Curing Metastatic Breast Cancer
Journal of Oncology Practice, 2016Metastatic breast cancer is generally considered incurable, and this colors doctor-patient interactions for patients with metastatic disease. Although true for most patients, there appear to be important exceptions, instances where long-term disease-free survival occurs. Although these instances are few in number, they suggest the possibility of cure.
openaire +2 more sources
CTCs in Metastatic Breast Cancer
2012Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch(®) system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients.
Giordano A., Cristofanilli M.
openaire +3 more sources
Cutaneous Metastatic Breast Cancer
Clinical Journal of Oncology Nursing, 2002Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer deaths among women in the United States. Many women diagnosed with breast cancer will achieve a cure with surgery followed by adjuvant chemotherapy, hormonal therapy, or radiation therapy; however, some breast cancer survivors will develop locally ...
openaire +2 more sources
2019
De novo Stage IV breast cancer compromises 5–6% of woman with breast cancer. Systemic staging at the time of initial presentation is recommended for patients with clinical Stage IIIA disease or patients who have symptoms concerning for metastatic disease. Patients were suspected to have metastatic disease should be referred to medical oncology.
Zeynep Bostanci, Laura Kruper
openaire +2 more sources
De novo Stage IV breast cancer compromises 5–6% of woman with breast cancer. Systemic staging at the time of initial presentation is recommended for patients with clinical Stage IIIA disease or patients who have symptoms concerning for metastatic disease. Patients were suspected to have metastatic disease should be referred to medical oncology.
Zeynep Bostanci, Laura Kruper
openaire +2 more sources
2010
Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative.
Tejal A. Patel, Edith A. Perez
openaire +1 more source
Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative.
Tejal A. Patel, Edith A. Perez
openaire +1 more source